A novel method for detecting the cellular stemness state in normal and leukemic human hematopoietic cells can predict disease outcome and drug sensitivity.


Journal

Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895

Informations de publication

Date de publication:
08 2019
Historique:
received: 15 09 2018
accepted: 20 12 2018
revised: 02 12 2018
pubmed: 2 2 2019
medline: 29 10 2019
entrez: 2 2 2019
Statut: ppublish

Résumé

Acute leukemia is an aggressive blood malignancy with low survival rates. A high expression of stem-like programs in leukemias predicts poor prognosis and is assumed to act in an aberrant fashion in the phenotypically heterogeneous leukemia stem cell (LSC) population. A lack of suitable genome engineering tools that can isolate LSCs based on their stemness precludes their comprehensive examination and full characterization. We hypothesized that tagging endogenous stemness-regulatory regions could generate a genome reporter for the putative leukemia stemness-state. Our analysis revealed that the ERG  + 85 enhancer region can serve as a marker for stemness-state and a fluorescent lentiviral reporter was developed that can accurately recapitulate the endogenous activity. Using our novel reporter, we revealed cellular heterogeneity in several leukemia cell lines and patient-derived samples. Alterations in reporter activity were associated with transcriptomic and functional changes that were closely related to the hematopoietic stem cell (HSC) identity. Notably, the differentiation potential was skewed towards the erythro-megakaryocytic lineage. Moreover, an ERG  + 85

Identifiants

pubmed: 30705411
doi: 10.1038/s41375-019-0386-z
pii: 10.1038/s41375-019-0386-z
doi:

Substances chimiques

ERG protein, human 0
Transcriptional Regulator ERG 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2061-2077

Auteurs

Muhammad Yassin (M)

Department of Pathology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel.

Nasma Aqaqe (N)

Department of Pathology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel.

Abed Alkader Yassin (AA)

Department of Pathology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel.

Peter van Galen (P)

Center for Cancer Research, Massachusetts General Hospital, Boston, MA, 02114, USA.

Eitan Kugler (E)

Department of Pediatric Hemato-Oncology, Schneider Children Medical Center, Petah Tikva, Israel.
The Gene Development and Environment Pediatric Research Institute, Pediatric Hemato-Oncology, Edmond and Lily Safra Children's Hospital, Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
Department of Molecular Human Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel.

Bradley E Bernstein (BE)

Center for Cancer Research, Massachusetts General Hospital, Boston, MA, 02114, USA.

Maya Koren-Michowitz (M)

Hematology Division, Chaim Sheba Medical Center, Tel-Hashomer, Israel.

Jonathan Canaani (J)

Hematology Division, Chaim Sheba Medical Center, Tel-Hashomer, Israel.

Arnon Nagler (A)

Hematology Division, Chaim Sheba Medical Center, Tel-Hashomer, Israel.

Eric R Lechman (ER)

Princess Margaret Cancer Centre, University Health Network and Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.

John E Dick (JE)

Princess Margaret Cancer Centre, University Health Network and Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.

Erno Wienholds (E)

Princess Margaret Cancer Centre, University Health Network and Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.

Shai Izraeli (S)

Department of Pediatric Hemato-Oncology, Schneider Children Medical Center, Petah Tikva, Israel.
The Gene Development and Environment Pediatric Research Institute, Pediatric Hemato-Oncology, Edmond and Lily Safra Children's Hospital, Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
Department of Molecular Human Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel.

Michael Milyavsky (M)

Department of Pathology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel. mmilyavsky@post.tau.ac.il.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH